- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07738120
Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III (ExeRVIEM III)
28 de julho de 2026 atualizado por: Pablo Campo-Prieto, University of Vigo
Effects of a Physiotherapy Program With High-Intensity Exercise and Immersive Virtual Reality in Multiple Sclerosis: Randomized Controlled Trial
TITLE: Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III.
INTRODUCTION: Multiple sclerosis (MS) is a chronic neuroimmunological and degenerative disease characterized by demyelination within the central nervous system.
Its clinical course involves motor impairment, sensory disturbances, cognitive dysfunction, and a progressive decline in functional independence.
MS is one of the leading causes of non-traumatic disability in young adults.
This highlights the considerable impact of the disease, both in terms of healthcare burden and healthcare expenditure.
Within this context, therapeutic exercise has evolved from being considered potentially harmful to being recognized as a safe and effective intervention capable of improving gait, balance, cardiorespiratory fitness, fatigue, and quality of life in people with MS.
A model has been proposed for prescribing and progressing exercise at different stages of MS: passive range-of-motion exercises designed for patients with the most severe symptoms, a second stage incorporating active muscle-strengthening exercises, and finally, integrated exercise programs that incorporate strength, endurance, balance, and coordination training.
Evidence from systematic reviews and meta-analyses shows that structured exercise (including high-intensity protocols when performed under supervision) is safe and can improve functional outcomes.
Our ExeRVIEM III project (Physiotherapy program with High-Intensity Exercise Program and Immersive Virtual Reality in Multiple Sclerosis) represents a novel strategy to facilitate rehabilitation exercise programs using head-mounted virtual reality displays.
HYPOTHESIS: The ExeRVIEM III project, based on training physical function in people with MS, is feasible and safe, and could have a potential clinical impact in the motor and cognitive domains, as well as applicability in community settings, such as patient associations.
GENERAL OBJECTIVES: 1.1 To design and implement an ExeRVIEM III exercise program/protocol for people with MS. 1.2 To evaluate the safety of the high-intensity virtual reality exercise program.
SPECIFIC OBJECTIVES: 2.1 To analyze the possible changes in disability, functional variables, cognitive domains and biomarkers in the short and medium term in people who attend a patient association and carry out the ExeRVIEM III exercise program for people with MS.
METHODOLOGY: A randomized controlled trial, double-arm (experimental and control group) study will be conducted at a patient association (Santiago de Compostela, Spain).
The intervention will consist of an 6-month supervised virtual rehabilitation program, with two weekly sessions on alternate days, in addition to the standard rehabilitation prescribed by the patient association clinical team (physiotherapy, occupational therapy, and cognitive training sessions).
An inmersive virtual reality (IVR) body combat exercise videogame will be used, administered via a virtual reality headset.
In accordance with clinical guidelines for IVR, sessions will be intentionally brief (10 minutes) to minimize cybersickness and excessive fatigue.
Assessments will be conducted at baseline (week 0) and immediately after the intervention (week 24).
Demographic and clinical data will also be collected, including sex, age, comorbidities, disease duration, MS subtype, and pharmacological treatment.
Assessments will be conducted at the patient association and in the Neurology Department of the referral hospital.
Feasibility, safety, strength parameters, dual-task performance and fatigue levels assessments will be performed at the patient association by physiotherapists, while the remaining assessments will be completed at the hospital by a neurologist specializing in MS.
The content of the assessments will be: Patient characteristics that will include data on age, sex, years since diagnosis, MS subtype, and pharmacological treatment.
Feasibility: Number of virtual sessions attended by each participant (adherence rate via registration sheet).
Rate Perceived Effort using the modified Borg scale, which measures the level of perceived exertion on a scale of 0 to 10 from no effort to maximum effort.
Safety: adverse events using the Simulator Sickness Questionnaire (SSQ).Strength parameters using Five times sit to stand test (FTSST) and handgrip test.
Functional mobility will be assessed using Timed and Go test (TUG) and with dual task performance using TUG-cog.
Level of fatigue using the Fatigue Severity Scale (FSS).
Level of disability: using the Expanded Disability Status Scale (EDSS).Gait will be evaluated using the 25Foot Walk Test (25FWT).
Manual dexterity will be assessed using 9-Hole Peg Test (9HPT).
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
30
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Pablo Campo-Prieto, PhD
- Número de telefone: 986801770
- E-mail: pcampo@uvigo.gal
Locais de estudo
-
-
-
Pontevedra, Espanha
- Recrutamento
- University of Vigo
-
Contato:
- Dr. Pablo Campo Prieto, PhD
- Número de telefone: +034 986801750
- E-mail: pcampo@uvigo.gal
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- ≥18 years of age.
- Confirmed diagnosis of MS.
- Stable disease with no relapse in the previous 6 weeks.
- Patients who will be take follow up by a neurologist at the referral hospital and will be members of the patient association.
- Ability to perform moderate exercise.
- Capacity to provide informed consent.
Exclusion Criteria:
- Comorbidities that hinder the development of the VR program
- Visual or vestibular impairment that would contraindicate VR use.
- Recent changes in disease modifying therapy.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: ExeRVIEM III Protocol + Standard rehabilitation
Virtual exercise based program + Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
The intervention will consist of a supervised virtual rehabilitation program delivered over 6 months, with two sessions per week on alternating days.
An Immersive Virtual Reality body combat-based exergame executed through a VR headset will be used.
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
|
Comparador Ativo: Standard rehabilitation
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Prazo: Baseline
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability.
|
Baseline
|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Prazo: week 24
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability
|
week 24
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Prazo: Baseline
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Baseline
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Prazo: Week 24
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Week 24
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Prazo: Baseline
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Baseline
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Prazo: Week 24
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Week 24
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Prazo: Baseline
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Baseline
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Prazo: Week 24
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Week 24
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Prazo: Baseline
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Baseline
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Prazo: Week 24
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Week 24
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Prazo: Baseline
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movement (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance.
|
Baseline
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Prazo: Week 24
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance
|
Week 24
|
|
Functional mobility evaluated by five timed and go test (TUG)
Prazo: Baseline
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Baseline
|
|
Functional mobility evaluated by five timed and go test (TUG)
Prazo: Week 24
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Week 24
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Prazo: Baseline
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times indicate better performance.
|
Baseline
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Prazo: Week 24
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times better performance.
|
Week 24
|
|
Upper limbs strength evaluated by handgrip test
Prazo: Baseline
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Baseline
|
|
Upper limbs strength evaluated by handgrip test
Prazo: Week 24
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Week 24
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Prazo: Baseline
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Baseline
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Prazo: Week 24
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Week 24
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Pablo Campo-Prieto, PhD, University of Vigo
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
6 de outubro de 2025
Conclusão Primária (Estimado)
31 de julho de 2026
Conclusão do estudo (Estimado)
7 de agosto de 2026
Datas de inscrição no estudo
Enviado pela primeira vez
22 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
28 de julho de 2026
Primeira postagem (Real)
31 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
31 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
28 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HEALTHYFIT-UVIGO 3/2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .